FDA Advisory Panel Recommends BPC-157 for Compounding List

The committee's decision during its July 23, 2026, meeting defied the initial stance of FDA review staff, who had formally proposed excluding both BPC-157 free base and acetate from the list. Because the recommendation is advisory, it does not constitute a final regulatory action or an official endorsement of the peptide's safety or efficacy by the agency. FDA documents emphasize that BPC-157 lacks both an applicable USP/NF drug-substance monograph and status as a component of any FDA-approved medication.

Clinical evidence for the peptide remains largely theoretical. A 2025 systematic review published in the HSS Journal identified 36 total studies, yet only one was clinical in nature, with the remaining 35 limited to preclinical research. This lack of human safety data means that findings from laboratory or animal models cannot be extrapolated to support claims regarding human treatment outcomes or healing. For patients, the committee vote represents a step in administrative rulemaking rather than a signal of proven medical benefit.